Monday, April 10, 2017 2:50:59 PM
LINK:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=11987431
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 5, 2017
INVO BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Nevada
333-147330
20-4036208
(State or other jurisdiction of
(Commission
(I.R.S. Employer
Incorporation)
File Number)
Identification No.)
407R Mystic Avenue, Suite 34C, Medford, MA 02155
(Address of principal executive offices) (Zip Code)
(978) 878-9505
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 FR 240.13e-4(c))
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
In the evening of April 5, 2017, Claude Ranoux submitted his letter of resignation effective immediately as a member of the Board of Directors to INVO Bioscience, Inc.’s Board of Director’s Chairperson and CEO Kathleen Karloff. Claude Ranoux stated, “Recent events with respect to the operation of the Board of Directors have limited my ability to effectively serve the company as director.”
Claude Ranoux did not serve on any committee of the Board of Directors at the time of his resignation.
Due to disagreements on how to run the business, Claude Ranoux had initially indicated that he wanted Kathleen Karloff be replaced as an officer. Instead, as previously reported by the Corporation, on September 20, 2016 the Board of Directors replaced Claude Ranoux as President and Treasurer, and removed Claude Ranoux as Chief Scientist, of the Corporation, with Kathleen Karloff then being elected Chairman of the Board, President and CEO, and Robert Bowdring being elected Treasurer and Secretary of the Corporation. Claude Ranoux voted against those changes.
Since those changes Dr. Ranoux has voted against virtually all of the actions taken by the Board of Directors, which actions were approved by Ms. Karloff and Mr. Bowdring. Due to these disagreements, Dr. Ranoux has indicated his desire to replace Ms. Karloff and Mr. Bowdring as directors as well as change the Corporation’s management.
The Board of Directors believes Dr. Ranoux’s resignation was caused by Dr. Ranoux ceasing to be the President, Treasurer and Chief Scientist of the Corporation, the election of Ms. Karloff and Mr. Bowdring to their new officer positions.
Dr. Ranoux’s resignation letter is attached as Exhibit 17
A special telephonic Board of Directors meeting was called at 7:00 PM April 5, 2017, at which the Board of Directors discussed and accepted Claude Ranoux’s resignation as a director. The Board determined that it would review a list of potential candidates to fill the vacancy created on the Board of Directors by Dr. Ranoux’s resignation. A Board of Directors meeting had been previously scheduled for April 7, 2017.
INVO Bioscience would like to thank Claude Ranoux for his efforts over the years.”
Item 9.01
Financial Statements and Exhibits
Exhibit Number
Description
17
Resignation letter dated April 5, 2017.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INVO Bioscience, Inc. Date: April 7, 2017
By:/s/ Kathleen T Karloff
Kathleen T Karloff
chief Executive Officer and Chairman of the Board of Directors
Exhibit 17
April 5 , 2017
BY EMAIL AND FEDERAL EXPRESS
Board of Directors
INVO Bioscience, Inc.
Attn: Kathleen Karloff
Chairperson and CEO
407R Mystic Avenue
Suite 34C ,
Medford, MA 02155
Dear Ms. Karloff:
This lette r is to indicate my intention to resign from the Board of Directors of INVO Bioscience Inc. , effective immediately.
Recent events with respect to the operation of the Board of Directors have limited my ability to effectively serve the company as a director. I appreciate the opportunity to have served the company and its shareholders since its inception .
Sincerely yours ,
/s/ Claude Ranoux
Claude Ranoux
cc: Robert J. Bowdring
Recent INVO News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 09:21:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:06:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 01:00:36 PM
- INVO Reports Record Second Quarter 2024 Financial Results with 481% Revenue Growth and a $1.1 Million Improvement to Adjusted EBITDA • GlobeNewswire Inc. • 08/14/2024 01:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 05/21/2024 08:39:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:51:16 PM
- INVO Reports Record First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:30:18 PM
- Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
- INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
- NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
- NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
- INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM